Pulmonary Circulation, 2nd edition

Andrew J Peacock is Professor of Medicine, Consultant Respiratory Physician and Director, Scottish Pulmonary Vascular Unit, Western Infirmary, Glasgow, UK Lewis J Rubin is Professor of Medicine and Director, Pulmonary Vascular Center at the University of California, San Diego School of Medicine, La Jolla, USA

1. Functional structure of the pulmonary circulation. J Gil (New York)
2. Pulmonary vascular function. Robert Naeije (Brussels)
3. Pathology of pulmonary vascular disease. Rubin Tuder (John's Hopkins, USA)
4. Hypoxic pulmonary vasoconstriction and hypertension. Ken Weir (Minneapolis) and Andrea Olschewski (Giessen, Germany)
5. Pulmonary vascular re-modelling. Nick Morrell (Cambridge, U.K.)
6. Genetics. Heather Mortimer & Jane Morse
7. Clinical features. Andrew J Peacock (Glasgow)
8. Echocardiography. Adam Torbicki (Warsaw)
9. Imaging (including CXR, CT, MR and radionucleide). Richard Coulden (Cambridge)
10. Cardiac catheterization. Bertrum Groves & David Badesch (Denver, Colorado)
11. An integrated approach to the diagnosis of PHT (incl screening, when to biopsy, what imaging technique and when etc.). Michael McGoon (Mayo Clinic, U.S.A)
12. Classification and clinical features of PHT. Stuart Rich (Illinois, USA)
13. Pulmonary arterial hypertension
13.1 Pathobiology of pulmonary arterial hypertension. Norbert Voelkel (Denver, Colorado)
13.2 Diseases associated with pulmonary arterial hypertension
13.3 Treatment
13.3.1 Conventional medical therapies (incl anticoagulants, calcium channel antagonists, inotropic agents, diuretics, supplemental oxygen). Nazzareno Galie (Bologna, Italy)
13.3.2 Disease modifying therapies
13.3.2.1 Intravenous prostacyclin in pulmonary arterial hypertension. Victor Tapson (Duke, NC)
13.3.2.2 Inhaled iloprost. Horst Olschewski (Germany)
13.3.2.3 Oral and subcutaneous prostacyclin analogues.Vallerie McLaughlin (Chicago, U.S.A)
13.3.2.4 Inhaled nitric oxide. Joanna Pepke-Zaba and Keith MacNeil (Cambridge, UK)
13.3.2.5 Endothelin antagonistsRick Channick (La Jolla, U.S.A)
13.3.2.6 Novel medical approaches – growth inhibitors.Marlene Rabinovitch (Toronto, Canada)
13.3.3 Surgical therapies
13.3.3.1 Transplantation. Paul Corris (Newcastle, U.K)
13.3.3.2 Atrial septostomy. Julio Sandoval (Mexico City)
13.3.4 An integrated approach to the treatment of PAHT. Gerald Simonneau (Paris)
14.1 Diagnosis and treatment of left heart disease. Simon Gibbs (London, UK)
14.2 Pulmonary venous occlusive disease. Charles Hales and Barbara Cockrill (Harvard, USA)
14.3 Hemangiomatosis. David Langleben (Montreal)
15.1 Pulmonary hypertension due to chronic hypoxic lung disease (incl COPD, interstitial lung disease, parenchymal disease). Emmanuel Weitzenblum (Strasbourg, France)
15.2 Pulmonary hypertension in sleep disorders and breathing. John Stradling (Oxford, U.K.)
15.3 An integrated approach to the treatment of pulmonary hypertension due to hypoxic lung disease (incl diuretics, oxygen, NO, other vasodilators etc) William MacNee (Edinburgh, Scotland)
16. Acute pulmonary thromboembolism
16.1 Diagnosis. Arnaud Perrier (Geneva, Switzerland)
16.2 Treatment. Sam Goldhaber (Harvard, USA)
17. Chronic thromboembolic pulmonary hypertension: pathophysiology, diagnosis and treatment including thromboendarterectomy. Peter Fedullo, William Auger & Stuart Jamieson (San Diego, U.S.A)
18. Pulmonary vascular tumors. Kim Kerr (San Diego, USA)
19. Primary pulmonary hypertension in children.Robyn Barst (New York)
20. Persistent pulmonary hypertension of the newborn: strategies in clinical management. Steve Abman (Denver, U.S.A.)
21. Effects of mechanical ventilation on the pulmonary circulation. Michael Pinsky (Pittsburgh)
22. Effects of lung injury on the pulmonary circulation. Tim Evans (London)
23. Pharmacological manipulation of the pulmonary circulation in critically ill patients. Jean-Louis Vincent (Brussels)
24. High altitude, high altitude pulmonary edema and the pulmonary circulation. Marco Maggiori (Switzerland) and Peter Bartsch (Heidelberg, Germany)
25. Pulmonary circulation in the underwater environment. Stephen Watt (Aberdeen, U.K.)
26. Fetal lung circulation. Jack Reeves, Steve Abman & Kurt Stenmark (Denver, Colorado)
27. Hepato-pulmonary syndrome Michael Krowka (Mayo, Rochester, USA)
28. Pulmonary arteriovenous malformations. Claire Shovlin (London, U.K.)